RT Journal Article
SR Electronic
T1 First imported Cases of MPXV Clade Ib in Goma, Democratic Republic of the Congo: Implications for Global Surveillance and Transmission Dynamics
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.12.24313188
DO 10.1101/2024.09.12.24313188
A1 Mukadi-Bamuleka, Daniel
A1 Kinganda-Lusamaki, Eddy
A1 Mulopo-Mukanya, Noella
A1 Amuri-Aziza, Adrienne
A1 O’Toole, Áine
A1 Modadra-Madakpa, Brigitte
A1 Ndongala, Guy Mutombo
A1 Vakaniaki, Emmanuel Hasivirwe
A1 Merritt, Sydney
A1 Kacita, Cris
A1 Maboko, Gaston Lubambo
A1 Makangara-Cigolo, Jean-Claude
A1 Ngimba, Michel
A1 Lokilo, Emmanuel
A1 Pukuta-Simbu, Elisabeth
A1 Luakanda, Gradi
A1 Bodisa-Matamu, Tavia
A1 Kalimuli, Zephanie Paluku
A1 Akil-Bandali, Prince
A1 Kavira, Sifa
A1 Jansen, Daan
A1 Kamaliro, Adèle Kavira
A1 Muhindo-Milonde, Emile
A1 Mufungizi, Jeriel
A1 Hamisi, Yves Birindwa
A1 Kavunga, Hugo
A1 Tshiani, Olivier
A1 Nundu, Sabin S.
A1 Liesenborghs, Laurens
A1 Hoff, Nicole A.
A1 Nachega, Jean
A1 Shongo, Robert
A1 Ayouba, Ahidjo
A1 Pilarowski, Genay
A1 Mangolopa, Alain Kakule
A1 Ebondo, Amos Kiuka
A1 Low, Nicola
A1 Shaw, Souradet Y.
A1 Wilkinson, Sam
A1 Tessema, Sofonias Kifle
A1 Subissi, Lorenzo
A1 Delaporte, Eric
A1 Vercauteren, Koen
A1 Wawina-Bokalanga, Tony
A1 Rimoin, Anne W
A1 Peeters, Martine
A1 Loman, Nicholas
A1 Rambaut, Andrew
A1 Muyembe-Tamfum, Jean-Jacques
A1 Hensley, Lisa E.
A1 Kindrachuk, Jason
A1 Mbala-Kingebeni, Placide
A1 Ahuka-Mundeke, Steve
YR 2024
UL http://medrxiv.org/content/early/2024/09/16/2024.09.12.24313188.abstract
AB The ongoing national mpox outbreak in the Democratic Republic of the Congo has resulted in more >30,000 suspected cases in the country from January 2023 to August 2024. While these historic case totals have been driven by primarily by zoonosis, the emergence of Clade Ib monkeypox virus (MPXV), which is connected to more sustained human-to-human transmission, has been associated with increasing public health impacts in eastern DRC. First identified in South Kivu province, Clade Ib MPXV has been identified in multiple non-endemic East African countries for the first time. In DRC, there have been concerns over broader Clade Ib expansion in the country that could further complicate containment and mitigation responses. Here, we report the first introductions of Clade Ib into North Kivu province, including within internal displacement camps, with suspected close contact transmission that includes non-intimate contacts and children. These findings demonstrate that mpox case investigations and community messaging campaigns should include considerations for non-sexual contact-mediated transmission of Clade Ib that includes children <15 years.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Department of Defense, Defense Threat Reduction Agency, Monkeypox Threat Reduction Network; and USDA Non-Assistance Cooperative Agreement #20230048; Africa Pathogen Genomics Initiative helped acquiring and maintaining the sequencer; Agence Francaise de Developement through the AFROSCREEN project (grant agreement CZZ3209, coordinated by ANRS-MIE Maladies infectieuses emergentes in partnership with Institut de Recherche pour le Developpement (IRD) and Pasteur Institute) for laboratory support and PANAFPOX project funded by ANRS-MIE ; Belgian Directorate-general Development Cooperation and Humanitarian Aid and the Research Foundation - Flanders (FWO, grant number G096222 N to L.L.); the International Mpox Research Consortium (IMReC) through funding from the Canadian Institutes of Health Research and International Development Research Centre (grant no. MRR-184813); US NIAID/NIH grant number U01AI151799 through Center for Research in Emerging Infectious Disease-East and Central Africa (CREID-ECA); E.L. received a PhD grant from the French Foreign Office. We acknowledge the support of the Wellcome Trust (Collaborators Award 206298/Z/17/Z, ARTIC network).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this investigation was provided by the Ministry of Higher and University Education, School of Public Health Ethics Committee, University of Kinshasa, DRC, (ESP/CE/05/2023) as part of the national surveillance activities and carried out in the public interest by the Ministry of Health, the Democratic Republic of the Congo. All activities described were undertaken as part of regular public health surveillance conducted and approved directly by the Ministry of Health, Democratic Republic of the Congo. Data was provided by the National Programme for Control of Mpox and Viral Haemorrhagic Fevers and the National Institute for Biomedical Research, the Democratic Republic of the Congo, as part of the case investigations. No written informed consent for research was provided as the analyses conducted in this study were done retrospectively and the information and diagnostic samples were collected for surveillance and clinical care purposes.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors